Clinical study of the acute effects of intravenous nifekalant on the defibrillation threshold in patients with persistent and paroxysmal atrial fibrillation

Circulation Journal

Volumn 72, Issue 1, 2008, Pages 76-80

  Okishige, Kaoru ^a   Uehara, Hiroki ^a   Miyagi, Naoto ^a   Nakamura, Kentarou ^a   Azegami, Kouji ^a   Wakimoto, Hirofumi ^a   Ohba, Kageyuki ^a   Hirao, Kenzo ^b   Shimabukuro, Mitsuo ^c   Isobe, Mistuaki ^b  

^a YOKOHAMA CITY MINATO RED CROSS HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Antiarrhythmic agent; Atrial fibrillation; Defibrillation; Defibrillation threshold; Nifekalant

Indexed keywords

NIFEKALANT; ANTIARRHYTHMIC AGENT; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL ARTICLE; CLINICAL TRIAL; DEFIBRILLATION; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART ARREST; HEART ATRIUM FIBRILLATION; HUMAN; MALE; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PREDICTION; QT PROLONGATION; SINUS RHYTHM; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT REFUSAL; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COMBINED MODALITY THERAPY; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; TREATMENT OUTCOME;

EID: 39849103191     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.76     Document Type: Article

References (26)

1. Echt DS, Black JN, Barbey JT, Coxe DR, Cato E. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Circulation 1989; 79: 1106-1117.
2. Fain ES, Dorian P, Davy JM, Kates RE, Winkle RA. Effects of encainide and its metabolites on energy requirements for defibrillation. Circulation 1986; 77: 397-405.
3. Hernandez R, Mann DE, Breckinridge S, Williams GR, Reiter MJ. Effects of flecainide on defibrillation thresholds in the anesthetized dog. J Am Coll Cardiol 1989; 14: 777-781.
4. Wang M, Dorian P. DL and D sotalol decrease defibrillation energy requirements. Pacing Clin Electrophysiol 1989; 12: 1522-1529.
5. Wesley RC, Farkhani F, Morgan D, Zimmerman D. Ibutilide enhanced defibrillation via plateau sodium current activation. Am J Physiol 1993; 264: H1269-H1274.
6. Kerber RE, Pandian NG, Hoyt R. Effect of ischemia, hypertrophy, hypoxia, acidosis and alkalosis on canine defibrillation. Am J Physiol 1979; 98: 345-350.
7. Ruffy R, Scheinman K, Monje E. Beta-adrenergic modulation of direct defibrillation energy in anesthetized dog heart. Am J Physiol 1985; 248: H674-H677.
8. Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drugs, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 1993; 109: 157-163.
9. Sato R, Koumi S, Hisatome I, Takai H, Aida Y, Oyaizu M, et al. A new class III antiarrhythmic drug, MS-551, blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes. J Pharmacol Exp Ther 1995; 274: 469-474.
10. Murakawa Y, Yamashita T, Kanese Y, Omata M. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? J Am Coll Cardiol 1997; 29: 688-692.
11. Kerber RE, Martins JB, Kienzle MG. Energy, current and success in defibrillation and cardioversion: Clinical studies using an automated impedance based method of energy adjustment. Circulation 1988; 77: 1038-1052.
12. Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340: 1849-1854.
13. Lai LP, Lin JL, Lien WP, Tseng YZ, Huang SK. Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: An assessment of the electrophysiological effects by biatrial basket electrodes. J Am Coll Cardiol 2000; 35: 1434-1441.
14. Ujhelyi MR, O'Rangers EA, Chow MSS, Fan C, Kluger J. Defibrillation energy requirements during moricizine and combination antiarrhythmic therapy. J Cardiovasc Pharmacol 1992; 20: 932-939.
15. Peters W, Gang ES, Okazaki H. Acute effects of intravenous propafenone on the internal ventricular defibrillation threshold in the anesthetized dog. Am Heart J 1991; 122: 1355-1360.
16. Fogoros RN. Amiodarone-induced refractoriness to cardioversion. Ann Intern Med 1984; 100: 699-700.
17. Movsowitz C, Marchlinsky FE. Interactions between implantable cardioverter-defibrillators and class III agents. Am J Cardiol 1998; 82: 41I-48I.
18. Hohnloser SH, Dorian P, Roberts R, Gent M, Israel CW, Fain E, et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold: The optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006; 114: 104-109.
19. Murakawa Y, Yamashita T, Kanese Y, Omata M. Do the effects of antiarrhythmic drugs on defibrillation efficacy vary among different shock waveforms? Pacing Clin Electrophysiol 1998; 21: 1901-1908.
20. Murakawa Y, Yamashita T, Kanese Y, Omata M. Effect of class III antiarrhythmic drug on the configuration of dose response curve for defibrillation. Pacing Clin Electrophysiol 1999; 22: 479-486.
21. Katoh T, Mitamura H, Matsuda N, Takano T, Ogawa S, Kasanuki H. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias. Circ J 2005; 69: 1237-1243.
22. Tahara Y, Kimura K, Kosuge M, Ebina T, Sumita S, Hibi K, et al. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Circ J 2006; 70: 442-446.
23. Yoshioka K, Amino M, Morita S, Nakagawa Y, Usui K, Sugimoto A, et al. can nifekalant hydrochloride be used as a first-line drug for cardiopulmonary arrest CPA)?: Comparative study of out-of-hospital CPA with acidosis and in-hospital CPA without acidosis. Circ J 2006; 70: 21-27.
24. Ujhelyi MR, Schur M, Frede T, Bottorff MB, Gabel M, Markel ML. Mechanisms of antiarrhythmic drug-induced changes in defibrillation threshold: Role of potassium and sodium channel conductance. J Am Coll Cardiol 1996; 27: 1534-1542.
25. Flaker G, Schuder J, McDaniel W. The effect of multiple shocks on canine cardiac defibrillation. Pacing Clin Electrophysiol 1990; 13: 1580-1584.
26. Rattes MF, Jones DL, Sharma AD. Defibrillation threshold: A simple and quantitative estimate of the ability to defibrillate. Pacing Clin Electrophysiol 1987; 10: 70-77.